Free Trial

Integrated Diagnostics (LON:IDHC) Trading Down 2.8% - Should You Sell?

Integrated Diagnostics logo with Medical background

Key Points

  • Integrated Diagnostics Holdings plc saw its share price decrease by 2.8%, trading at GBX 0.35 on Monday, with a drastic decline in trading volume.
  • The company has a market capitalization of £10.30 billion and a price-to-earnings ratio of 13.01, indicating average valuation metrics.
  • Integrated Diagnostics is a leading provider of diagnostic services in the Middle East and Africa, with core brands operating across multiple countries including Egypt and Saudi Arabia.
  • Interested in Integrated Diagnostics? Here are five stocks we like better.

Integrated Diagnostics Holdings plc (LON:IDHC - Get Free Report)'s share price traded down 2.8% on Monday . The stock traded as low as GBX 0.35 ($0.00) and last traded at GBX 0.35 ($0.00). 5,648 shares changed hands during mid-day trading, a decline of 99% from the average session volume of 385,943 shares. The stock had previously closed at GBX 0.36 ($0.00).

Integrated Diagnostics Stock Down 2.8%

The company has a market cap of £10.30 billion, a price-to-earnings ratio of 13.01, a PEG ratio of 7.65 and a beta of 0.59. The business has a fifty day moving average of GBX 0.35 and a two-hundred day moving average of GBX 0.36. The company has a current ratio of 1.59, a quick ratio of 0.75 and a debt-to-equity ratio of 45.72.

About Integrated Diagnostics

(Get Free Report)

IDH is a leading diagnostics services provider in the Middle East and Africa offering a broad range of clinical pathology and radiology tests to patients in Egypt, Jordan, Nigeria, Saudi Arabia, and Sudan. The Group's core brands include Al Borg, Al Borg Scan and Al Mokhtabar in Egypt, as well as Biolab (Jordan), Echo-Lab (Nigeria), Ultralab and Al Mokhtabar Sudan (both in Sudan), and Biolab KSA (Saudi Arabia).

Recommended Stories

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.

Should You Invest $1,000 in Integrated Diagnostics Right Now?

Before you consider Integrated Diagnostics, you'll want to hear this.

MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Integrated Diagnostics wasn't on the list.

While Integrated Diagnostics currently has a Hold rating among analysts, top-rated analysts believe these five stocks are better buys.

View The Five Stocks Here

Elon Musk's Next Move Cover

Explore Elon Musk’s boldest ventures yet—from AI and autonomy to space colonization—and find out how investors can ride the next wave of innovation.

Get This Free Report
Like this article? Share it with a colleague.

Featured Articles and Offers

Recent Videos

Palantir & AMD Earnings: Massive Options Setups Ahead
3 Value Plays Set to Explode
5 Stocks to BUY NOW in August 2025

Stock Lists

All Stock Lists

Investing Tools

Calendars and Tools

Search Headlines